Guardant Health (GH) said Tuesday that the Centers for Medicare and Medicaid Services has granted Advanced Diagnostic Laboratory Test, or ADLT, status for Guardant's Shield blood test to screen for colorectal cancer.
Guardant said the ADLT designation means the Shield test meets the criteria for providing clinical information that can't be obtained by any other method. The test was approved by the US Food and Drug Administration in 2024 for average-risk individuals 45 years old and older.
The company said the test will be reimbursed at $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。